Fractyl Health, Inc. - SIC # 3840 -

Ticker Exchange SIC # Website Latest Ticker
GUTS Nasdaq 3840 fractyl.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Fractyl Health, Inc.

Fractyl Health (GUTS) Tests Whether Revita Can Redefine Post-GLP-1 Weight Maintenance Economics - Jan 29th, 2026 11:16 pm
Fractyl Health Showcases 6-Month REMAIN-1 Data as Revita Curbs Post-GLP-1 Weight Regain - Jan 29th, 2026 10:12 am
BC-Most Active Stocks - Jan 29th, 2026 8:30 am
Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita® After GLP-1 Discontinuation - Jan 29th, 2026 5:00 am
Fractyl Health Appoints Lara Smith Weber as Chief Financial Officer to Support Commercial-Stage Preparedness - Jan 6th, 2026 5:00 am
Fractyl Health Enters a Catalyst-Rich 2026 Positioned to Define the Post-GLP-1 Weight Maintenance Therapeutic Category - Jan 5th, 2026 5:00 am
Analysts Keep Buy Ratings on Fractyl Health (GUTS) - Jan 3rd, 2026 4:19 am
Fractyl Health’s REVEAL-1 Study Shows Positive Six-Month Results for Revita in Maintaining Weight and Glycemic Control Post-GLP-1 Use - Dec 31st, 2025 9:12 am
With 58% institutional ownership, Fractyl Health, Inc. (NASDAQ:GUTS) is a favorite amongst the big guns - Dec 18th, 2025 4:53 am
Fractyl Health Announces Call of Tranche A Warrants Tied to August 2025 Public Offering Following Achievement of Clinical and Trading Milestones - Dec 15th, 2025 3:45 pm
Fractyl Health Reports Positive 6-Month REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure - Dec 2nd, 2025 5:00 am
Fractyl Health to Participate in the 8th Annual Evercore Healthcare Conference - Dec 1st, 2025 5:00 am
Fractyl Health Inc (GUTS) Q3 2025 Earnings Call Highlights: Pioneering Weight Loss Solutions ... - Nov 12th, 2025 10:01 pm
Fractyl Health Reports Third Quarter 2025 Results; Revita® Clinical Momentum Builds Toward 2026 Pivotal Readout and PMA Filing, Cash Runway Extended into Early 2027 - Nov 12th, 2025 2:05 pm
Fractyl Health to Report Third Quarter 2025 Financial Results and Provide Business Updates on November 12, 2025 - Nov 5th, 2025 5:00 am
Fractyl Health Unveils Potent Preclinical Data for Dual GIP/GLP-1 Gene Therapy RJVA-002 for Obesity - Oct 17th, 2025 7:59 am
Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity - Oct 7th, 2025 5:00 am
Fractyl Health (GUTS) Is Up 35.6% After Revita Shows Weight Loss Maintained Post-GLP-1 and $60M Raise - Sep 28th, 2025 4:53 am
Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock - Sep 26th, 2025 5:05 am
Fractyl Health Announces Groundbreaking Data from REMAIN-1 Midpoint Cohort Showing Revita® Maintained Weight Loss After GLP-1 Discontinuation - Sep 26th, 2025 5:00 am